1
|
McCarthy CI, Chou-Freed C, Rodríguez SS, Yaneff A, Davio C, Raingo J. Constitutive activity of dopamine receptor type 1 (D1R) increases CaV2.2 currents in PFC neurons. J Gen Physiol 2021; 152:151624. [PMID: 32259196 PMCID: PMC7201881 DOI: 10.1085/jgp.201912492] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 02/14/2020] [Accepted: 03/12/2020] [Indexed: 01/19/2023] Open
Abstract
Alterations in dopamine receptor type 1 (D1R) density are associated with cognitive deficits of aging and schizophrenia. In the prefrontal cortex (PFC), D1R plays a critical role in the regulation of working memory, which is impaired in these cognitive deficit states, but the cellular events triggered by changes in D1R expression remain unknown. A previous report demonstrated that interaction between voltage-gated calcium channel type 2.2 (CaV2.2) and D1R stimulates CaV2.2 postsynaptic surface location in medial PFC pyramidal neurons. Here, we show that in addition to the occurrence of the physical receptor-channel interaction, constitutive D1R activity mediates up-regulation of functional CaV2.2 surface density. We performed patch-clamp experiments on transfected HEK293T cells and wild-type C57BL/6 mouse brain slices, as well as imaging experiments and cAMP measurements. We found that D1R coexpression led to ∼60% increase in CaV2.2 currents in HEK293T cells. This effect was occluded by preincubation with a D1/D5R inverse agonist, chlorpromazine, and by replacing D1R with a D1R mutant lacking constitutive activity. Moreover, D1R-induced increase in CaV2.2 currents required basally active Gs protein, as well as D1R-CaV2.2 interaction. In mice, intraperitoneal administration of chlorpromazine reduced native CaV currents’ sensitivity to ω-conotoxin-GVIA and their size by ∼49% in layer V/VI pyramidal neurons from medial PFC, indicating a selective effect on CaV2.2. Additionally, we found that reducing D1/D5R constitutive activity correlates with a decrease in the agonist-induced D1/D5R inhibitory effect on native CaV currents. Our results could be interpreted as a stimulatory effect of D1R constitutive activity on the number of CaV2.2 channels available for dopamine-mediated modulation. Our results contribute to the understanding of the physiological role of D1R constitutive activity and may explain the noncanonical postsynaptic distribution of functional CaV2.2 in PFC neurons.
Collapse
Affiliation(s)
- Clara Inés McCarthy
- Electrophysiology Laboratory, Multidisciplinary Institute of Cell Biology, Universidad Nacional de La Plata, Consejo de Investigaciones Científicas y Técnicas, Comisión de Investigaciones de la Provincia de Buenos Aires, Buenos Aires, Argentina
| | - Cambria Chou-Freed
- Electrophysiology Laboratory, Multidisciplinary Institute of Cell Biology, Universidad Nacional de La Plata, Consejo de Investigaciones Científicas y Técnicas, Comisión de Investigaciones de la Provincia de Buenos Aires, Buenos Aires, Argentina
| | - Silvia Susana Rodríguez
- Electrophysiology Laboratory, Multidisciplinary Institute of Cell Biology, Universidad Nacional de La Plata, Consejo de Investigaciones Científicas y Técnicas, Comisión de Investigaciones de la Provincia de Buenos Aires, Buenos Aires, Argentina
| | - Agustín Yaneff
- Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Carlos Davio
- Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Jesica Raingo
- Electrophysiology Laboratory, Multidisciplinary Institute of Cell Biology, Universidad Nacional de La Plata, Consejo de Investigaciones Científicas y Técnicas, Comisión de Investigaciones de la Provincia de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
2
|
Chen ML, Wu S, Tsai TC, Wang LK, Tsai FM. Regulation of neutrophil phagocytosis of Escherichia coli by antipsychotic drugs. Int Immunopharmacol 2014; 23:550-7. [PMID: 25448498 DOI: 10.1016/j.intimp.2014.09.030] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Revised: 09/24/2014] [Accepted: 09/26/2014] [Indexed: 01/21/2023]
Abstract
Antipsychotic drugs (APDs) have been used to ease the symptoms of schizophrenia. APDs have recently been reported to regulate the immune response. Our previous studies revealed that the atypical APDs risperidone and clozapine and the typical APD haloperidol can inhibit the phagocytic ability of macrophages. Our research next determined the effects of APDs on the phagocytic ability of neutrophils, which are the most abundant type of white blood cells in mammals. Here we provide evidence that clozapine and haloperidol can induce increased phagocytic uptake of Escherichia coli by differentiated HL-60 cells and by purified human neutrophils. Furthermore, clozapine and haloperidol can increase the myeloperoxidase activity and IL-8 production in neutrophils. Our results also show that clozapine can inhibit E. coli survival within differentiated HL-60 cells. Furthermore, clozapine and haloperidol are shown to enhance cell surface Mac-1 expression and the activated AKT signaling pathway in purified neutrophils exposed to E. coli. These results indicate that clozapine and haloperidol can increase the phagocytic ability of neutrophils by increasing AKT activation when cells are exposed to bacteria.
Collapse
Affiliation(s)
- Mao-Liang Chen
- Department of Research, Taipei Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, New Taipei City, Taiwan
| | - Semon Wu
- Department of Research, Taipei Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, New Taipei City, Taiwan; Department of Life Science, Chinese Culture University, Shih Lin, Taipei, Taiwan
| | - Tzung-Chieh Tsai
- Department of Microbiology, Immunology and Biopharmaceuticals, National Chiayi University, Chiayi, Taiwan
| | - Lu-Kai Wang
- Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
| | - Fu-Ming Tsai
- Department of Research, Taipei Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, New Taipei City, Taiwan.
| |
Collapse
|
3
|
The vital role of constitutive GPCR activity in the mesolimbic dopamine system. Transl Psychiatry 2014; 4:e361. [PMID: 24518399 PMCID: PMC3944632 DOI: 10.1038/tp.2013.130] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2013] [Revised: 11/13/2013] [Accepted: 12/07/2013] [Indexed: 12/28/2022] Open
Abstract
The midbrain dopamine system has an important role in processing rewards and the stimuli associated with them, and is implicated in various psychiatric disorders. This system is tightly regulated by various G protein-coupled receptors (GPCRs). It is becoming increasingly clear that these receptors are not only activated by (endogenous) agonists but that they also exhibit agonist-independent intrinsic constitutive activity. In this review we highlight the evidence for the physiological role of such constitutive GPCR activity (in particular for cannabinoid 1, serotonin 2C and mu-opioid receptors) in the ventral tegmental area and in its output regions like the nucleus accumbens. We also address the behavioral relevance of constitutive GPCR signaling and discuss the repercussions of its abolition in dopamine-related psychiatric diseases.
Collapse
|
4
|
Zhang B, Albaker A, Plouffe B, Lefebvre C, Tiberi M. Constitutive activities and inverse agonism in dopamine receptors. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2014; 70:175-214. [PMID: 24931197 DOI: 10.1016/b978-0-12-417197-8.00007-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The concept of activation in the absence of agonists has been demonstrated for many GPCRs and is now solidified as one of the principal aspects of GPCR signaling. In this chapter, we review how dopamine receptors demonstrate this ability. Although difficult to prove in vivo due to the presence of endogenous dopamine and lack of subtype-selective inverse agonists and "pure" antagonists (neutral ligands), in vitro assays such as measuring intracellular cAMP, [(35)S]GTPγS binding, and [(3)H]thymidine incorporation have uncovered the constitutive activation of D1- and D2-class receptors. Nevertheless, because of limited and inconsistent findings, the existence of constitutive activity for D2-class receptors is currently not well established. Mutagenesis studies have shown that basal signaling, notably by D1-class receptors, is governed by the collective contributions of transmembrane domains and extracellular/intracellular loops, such as the third extracellular loop, the third intracellular loop, and C-terminal tail. Furthermore, constitutive activities of D1-class receptors are subjected to regulation by kinases. Among the dopamine receptor family, the D5 receptor subtype exhibits a higher basal signaling and bears resemblance to constitutively active mutant forms of GPCRs. The presence of its constitutive activity in vivo and its pathophysiological relevance, with a brief mention of other subtypes, are also discussed.
Collapse
Affiliation(s)
- Boyang Zhang
- Ottawa Hospital Research Institute (Neuroscience Program), Ottawa, Ontario, Canada; Departments of Medicine, Cellular & Molecular Medicine, Psychiatry, University of Ottawa, Ottawa, Ontario, Canada
| | - Awatif Albaker
- Ottawa Hospital Research Institute (Neuroscience Program), Ottawa, Ontario, Canada; Departments of Medicine, Cellular & Molecular Medicine, Psychiatry, University of Ottawa, Ottawa, Ontario, Canada
| | - Bianca Plouffe
- Department of Biochemistry, Université de Montréal, Montréal, Québec, Canada; Institut de recherche en immunologie, cancer, Montréal, Québec, Canada
| | - Caroline Lefebvre
- Ottawa Hospital Research Institute (Neuroscience Program), Ottawa, Ontario, Canada; Departments of Medicine, Cellular & Molecular Medicine, Psychiatry, University of Ottawa, Ottawa, Ontario, Canada
| | - Mario Tiberi
- Ottawa Hospital Research Institute (Neuroscience Program), Ottawa, Ontario, Canada; Departments of Medicine, Cellular & Molecular Medicine, Psychiatry, University of Ottawa, Ottawa, Ontario, Canada.
| |
Collapse
|
5
|
Chetrit J, Taupignon A, Froux L, Morin S, Bouali-Benazzouz R, Naudet F, Kadiri N, Gross CE, Bioulac B, Benazzouz A. Inhibiting subthalamic D5 receptor constitutive activity alleviates abnormal electrical activity and reverses motor impairment in a rat model of Parkinson's disease. J Neurosci 2013; 33:14840-9. [PMID: 24027284 PMCID: PMC6705171 DOI: 10.1523/jneurosci.0453-13.2013] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Revised: 07/25/2013] [Accepted: 08/08/2013] [Indexed: 11/21/2022] Open
Abstract
Burst firing has been reported as a pathological activity of subthalamic nucleus (STN) neurons in Parkinson's disease. However, the origin of bursts and their causal link with motor deficits remain unknown. Here we tested the hypothesis that dopamine D5 receptors (D5Rs), characterized by a high constitutive activity, may contribute to the emergence of burst firing in STN. We tested whether inhibiting D5R constitutive activity depresses burst firing and alleviates motor impairments in the 6-OHDA rat model of Parkinson's disease. Intrasubthalamic microinjections of either an inverse agonist of D5Rs, flupenthixol, or a D2R antagonist, raclopride, were applied. Behavioral experiments, in vivo and in vitro electrophysiological recordings, and ex vivo functional neuroanatomy studies were performed. Using [(5)S]GTPγ binding autoradiography, we show that application of flupenthixol inhibits D5R constitutive activity within the STN. Furthermore, flupenthixol reduced evoked burst in brain slices and converted pathological burst firing into physiological tonic, single-spike firing in 6-OHDA rats in vivo. This later action was mimicked by calciseptine, a Cav1 channel blocker. Moreover, the same treatment dramatically attenuated motor impairment in this model and normalized metabolic hyperactivity in both STN and substantia nigra pars reticulata, the main output structure of basal ganglia in rats. In contrast, raclopride as well as saline did not reverse burst firing and motor deficits, confirming the selective action of flupenthixol on D5Rs. These results are the first to demonstrate that subthalamic D5Rs are involved in the pathophysiology of Parkinson's disease and that administering an inverse agonist of these receptors may lessen motor symptoms.
Collapse
Affiliation(s)
- Jonathan Chetrit
- Université Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, and
| | - Anne Taupignon
- Université Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, and
| | - Lionel Froux
- Université Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, and
| | - Stephanie Morin
- Université Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, and
| | | | - Frédéric Naudet
- Université Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, and
| | - Nabila Kadiri
- Université Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, and
| | - Christian E. Gross
- Université Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, and
| | - Bernard Bioulac
- Université Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, and
| | - Abdelhamid Benazzouz
- Université Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, and
| |
Collapse
|
6
|
Sf9 cells: a versatile model system to investigate the pharmacological properties of G protein-coupled receptors. Pharmacol Ther 2010; 128:387-418. [PMID: 20705094 DOI: 10.1016/j.pharmthera.2010.07.005] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2010] [Accepted: 07/12/2010] [Indexed: 11/23/2022]
Abstract
The Sf9 cell/baculovirus expression system is widely used for high-level protein expression, often with the purpose of purification. However, proteins may also be functionally expressed in the defined Sf9 cell environment. According to the literature, the pharmacology of G-protein-coupled receptors (GPCRs) functionally reconstituted in Sf9 cells is similar to the receptor properties in mammalian cells. Sf9 cells express both recombinant GPCRs and G-proteins at much higher levels than mammalian cells. Sf9 cells can be grown in suspension culture, providing an inexpensive way of obtaining large protein amounts. Co-infection with various baculoviruses allows free combination of GPCRs with different G-proteins. The absence of constitutively active receptors in Sf9 cells provides an excellent signal-to background ratio in functional assays, allowing the detection of agonist-independent receptor activity and of small ligand-induced signals including partial agonistic and inverse agonistic effects. Insect cell Gα(i)-like proteins mostly do not couple productively to mammalian GPCRs. Thus, unlike in mammalian cells, Sf9 cells do not require pertussis toxin treatment to obtain a Gα(i)-free environment. Co-expression of GPCRs with Gα(i1), Gα(i2), Gα(i3) or Gα(o) in Sf9 cells allows the generation of a selectivity profile for these Gα(i/o)-isoforms. Additionally, GPCR-G-protein combinations can be compared with defined 1:1 stoichiometry by expressing GPCR-Gα fusion proteins. Sf9 cells can also be employed for ligand screening in medicinal chemistry programs, using radioligand binding assays or functional assays, like the steady-state GTPase- or [(35)S]GTPγS binding assay. This review shows that Sf9 cells are a versatile model system to investigate the pharmacological properties of GPCRs.
Collapse
|
7
|
D'Aoust JP, Tiberi M. Role of the extracellular amino terminus and first membrane-spanning helix of dopamine D1 and D5 receptors in shaping ligand selectivity and efficacy. Cell Signal 2010; 22:106-16. [DOI: 10.1016/j.cellsig.2009.09.020] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2009] [Accepted: 09/14/2009] [Indexed: 01/28/2023]
|
8
|
Sakihama T, Masuda K, Sato T, Doi T, Kodama T, Hamakubo T. Functional reconstitution of G-protein-coupled receptor-mediated adenylyl cyclase activation by a baculoviral co-display system. J Biotechnol 2008; 135:28-33. [DOI: 10.1016/j.jbiotec.2008.02.022] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2007] [Revised: 02/12/2008] [Accepted: 02/22/2008] [Indexed: 11/26/2022]
|
9
|
Uustare A, Reinart R, Rinken A. Modulation of dopamine D1 receptor signaling by adenosine A1 receptors in Sf9 cells requires expression of Gi proteins. Neurosci Lett 2006; 406:169-73. [PMID: 16935419 DOI: 10.1016/j.neulet.2006.07.051] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2006] [Revised: 06/27/2006] [Accepted: 07/07/2006] [Indexed: 11/19/2022]
Abstract
There are several evidences that some functions of D1 dopamine receptors can be modulated by colocalized adenosine A1 receptors. To elucidate the role of particular components of the receptor complex in the ligand binding and second messenger activation level we have used Sf9 cell expression system. The expression of D1 and A1 receptors was confirmed by proper binding of specific radioligands [3H]SCH23390 (Kd=1.1+/-0.1 nM, Bmax=2.2+/-0.1 pmol/mg protein) and [3H]DPCPX (Kd=2.1+/-0.8nM, Bmax=2.9+/-0.4 pmol/mg protein), respectively. The kinetics of [3H]SCH23390 binding corresponded to the simplest reversible bimolecular binding reaction of complex formation, with k(on)=0.20+/-0.02 min(-1)nM(-1) and k(off)=0.13+/-0.01 min(-1). Dopaminergic agonists increased the accumulation of cAMP in the transfected cells in concentration-dependent manner, indicating a correct coupling of receptor to second messenger system. The coupling of the A1 receptor to Gi proteins was confirmed by both GTPgammaS dependent agonist binding and inhibition of cAMP accumulation by N-cyclopentyladenosine (NCPA). Activation of the A1 receptor by NCPA had no significant influence on neither affinities of dopaminergic ligands nor the radioligand binding kinetics to the co-exprssed D1 receptors in Sf9 cell membranes. On the other hand, the activation of the A1 receptors inhibited the D1 receptor-specific accumulation of cAMP, but only in cells where Gi proteins were expressed with the receptors.
Collapse
MESH Headings
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology
- Adenosine/analogs & derivatives
- Adenosine/pharmacology
- Adenosine A1 Receptor Antagonists
- Animals
- Benzazepines/pharmacokinetics
- Binding, Competitive/drug effects
- Cell Line
- Cyclic AMP/metabolism
- Dopamine Agonists/pharmacology
- Dopamine Antagonists/pharmacokinetics
- Dose-Response Relationship, Drug
- Drug Interactions
- GTP-Binding Protein alpha Subunits, Gi-Go/genetics
- GTP-Binding Protein alpha Subunits, Gi-Go/metabolism
- Gene Expression/drug effects
- Gene Expression/physiology
- Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology
- Humans
- Radioligand Assay/methods
- Receptor, Adenosine A1/physiology
- Receptors, Dopamine D1/physiology
- Signal Transduction/physiology
- Spodoptera
- Transfection/methods
- Tritium/pharmacokinetics
- Xanthines/pharmacokinetics
Collapse
Affiliation(s)
- Ain Uustare
- Institute of Organic and Bioorganic Chemistry, University of Tartu, Tartu, Estonia
| | | | | |
Collapse
|
10
|
Jutkiewicz EM, Bergman J. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions. J Pharmacol Exp Ther 2004; 311:1008-15. [PMID: 15292458 DOI: 10.1124/jpet.104.071092] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Dopamine D1 ligands have been classified and ordered according to efficacy in both in vitro and in vivo studies. In the present experiments, dopamine D1 ligands reported to differ in in vitro efficacy were evaluated for efficacy-related effects on eye blinking in squirrel monkeys. Additional comparisons were made with the effects of D2 receptor agonists and indirect dopamine agonists. The results show that D1 agonists increased eye blinking in an efficacy-related manner, whereas the D1 receptor blocker SCH 39166 [(-)-trans-6,7,7alpha,8,9,13beta-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naphtho[2,1-b]azepine] only decreased rates of eye blinking. D1 high-efficacy agonists induced rates of eye blinking that were 2- to 3-fold greater than observed with dopamine D2 agonists and indirect agonists. In drug combination experiments, increases in eye blinking induced by the D1 high-efficacy agonist R-(+)-6-Br-APB [R-(+)-6-bromo-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide] were antagonized by both the D1 antagonist SCH 39166 and the lower efficacy agonist SKF 83959 [6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide], consistent with dopamine D1 receptor mediation of these behavioral effects. The dopamine D2 agonist (+)-PHNO [(+)-N-propyl-hydroxynaphthoxazine], which selectively activates dopamine D2 receptors, also attenuated D1 agonist-induced increase in eye blinking, suggesting that D2 receptor actions may inhibit D1-mediated increases in eye blinking. Overall, eye blink rate appears to be a robust behavioral measure that can be used to measure changes in dopaminergic D1 signaling and as a functional assay of agonist efficacy at dopamine D1 receptors.
Collapse
|
11
|
Cussac D, Pasteau V, Millan MJ. Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapine. Eur J Pharmacol 2004; 485:111-7. [PMID: 14757130 DOI: 10.1016/j.ejphar.2003.11.077] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Herein, we examined the direct coupling of human dopamine D1 receptors to G(s) proteins using an antibody capture assay together with a detection technique employing scintillation proximity assay beads. Using a specific antibody, dopamine (DA) and the selective dopamine D1 receptor agonists, 6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF81297) and 3-allyl-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF82958), behaved as high-efficacy agonists ( approximately 100%) in stimulating guanosine-5'-O-(3-[35S]thio)-triphosphate ([35S]GTP gamma S) binding to G(s) in L-cells, whereas 2,3,4,5,-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (SKF38393) displayed partial agonist properties (70%). The action of dopamine was specifically mediated by human dopamine D1 receptors inasmuch as the selective human dopamine D1 receptor antagonist, (R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-benzazepine-7-ol (SCH23390), blocked dopamine-induced [35S]GTP gamma S binding to G(s) with a pK(B) (9.29) close to its pK(i) (9.33). The antipsychotic agents, clozapine and haloperidol, displayed no intrinsic activity when tested alone and inhibited dopamine-stimulated G(s) activation with pK(B)'s of 6.7 and 7.3, respectively, values close to their pK(i) values at these sites. In conclusion, the use of an anti-G(s) protein immunoprecipitation assay coupled to scintillation proximity assays allows direct evaluation of the functional activity of dopamine D1 receptors ligands at the G protein level. Employing this novel technique, the typical and atypical antipsychotics, clozapine and haloperidol, respectively, both exhibited antagonist properties at dopamine D1 receptors.
Collapse
Affiliation(s)
- Didier Cussac
- Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125, Chemin de Ronde, 78290 Croissy-sur-Seine, France
| | | | | |
Collapse
|
12
|
Uustare A, Näsman J, Akerman KEO, Rinken A. Characterization of M2 muscarinic receptor activation of different G protein subtypes. Neurochem Int 2004; 44:119-24. [PMID: 12971914 DOI: 10.1016/s0197-0186(03)00103-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The M2 muscarinic acetylcholine receptor (mAChR) expressed in insect cells (Spodoptera frugiperda, Sf9) using the baculovirus system formed active functional complexes with coexpressed Gi as well as with Go proteins, while no complexes could be detected with internal G proteins. Comparison of the abilities of different muscarinic agonists and partial agonists to increase [35S]GTPgammaS binding revealed no significant differences between M2/Gi and M2/Go complexes neither with respect to affinities nor efficacies of the ligands studied. Coexpression with either G protein caused constitutive activity of the receptor amounting up to 66% of stimulable [35S]GTPgammaS binding. Muscarinic antagonists, like atropine, scopolamine and N-methylscopolamine, behaved as inverse antagonists with potencies in good agreement with their binding affinities to the receptor. The results implicate that the functional reconstitution of M2 muscarinic receptor with either Gi or Go proteins in insect cells provides a valuable tool for screening of potencies as well as efficacies of agonists, partial agonists and inverse agonists at this receptor.
Collapse
Affiliation(s)
- Ain Uustare
- Institute of Organic and Bioorganic Chemistry, University of Tartu, Jakobi Str. 2, EE-51014 Tartu, Estonia
| | | | | | | |
Collapse
|
13
|
Knight PJK, Pfeifer TA, Grigliatti TA. A functional assay for G-protein-coupled receptors using stably transformed insect tissue culture cell lines. Anal Biochem 2003; 320:88-103. [PMID: 12895473 DOI: 10.1016/s0003-2697(03)00354-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Insect cells are an underexplored resource for functional G-protein-coupled receptor (GPCR) assays, despite a strong record in biochemical (binding) assays. Here we describe the use of vectors capable of creating stably transformed insect cell lines to generate a cell-based functional GPCR assay. This assay employs the luminescent photoprotein aequorin and the promiscuous G-protein subunit Galpha16 and is broadly applicable to human GPCRs. We demonstrate that the assay can quantitate ligand concentration-activity relationships for seven different human GPCRs, can differentiate between partial and full agonists, and can determine rank order potencies for both agonists and antagonists that match those seen with other assay systems. Human Galpha16 improves signal strength but is not required for activity with some receptors. The coexpression of human and bovine betagamma subunits and/or phospholipase Cbeta makes no difference to agonist efficacy or potency. Two different receptors expressed in the same cell line respond to their specific agonists, and two different cell lines (Sf9 and High 5) are able to functionally detect the same expressed GPCR. Sf9 cells have the capability to produce fully functional human receptors, allied to a low background of endogenous receptors, and so are a valuable system for investigating orphan GPCRs and receptor dimerization.
Collapse
Affiliation(s)
- Peter J K Knight
- Department of Zoology, University of British Columbia, 6270 University Boulevard, Rm 3444, Vancouver, British Columbia, Canada, V6T 1Z4
| | | | | |
Collapse
|
14
|
Tumova K, Iwasiow RM, Tiberi M. Insight into the mechanism of dopamine D1-like receptor activation. Evidence for a molecular interplay between the third extracellular loop and the cytoplasmic tail. J Biol Chem 2003; 278:8146-53. [PMID: 12509438 DOI: 10.1074/jbc.m208059200] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A chimeric D1A dopaminergic receptor harboring the cytoplasmic tail (CT) of the D1B subtype (D1A-CTB) has been used previously to show that CT imparts high dopamine (DA) affinity and constitutive activity to the D1B receptors. However, the D1A-CTB chimera, unlike the D1B subtype, exhibits a significantly lower DA potency for stimulating adenylyl cyclase and a drastically lower maximal binding capacity (Bmax). Here, using a functional complementation of chimeric D1-like receptors, we have identified the human D1B receptor regions regulating the intramolecular relationships that lead to an increased DA potency and contribute to Bmax. We demonstrate that the addition of variant residues of the third extracellular loop (EL3) of the human D1B receptor into D1A-CTB chimera leads to a constitutively active mutant receptor displaying an increased DA affinity, potency, and Bmax. These results strongly suggest that constitutively active D1-like receptors can adopt multiple active conformations, notably one that confers increased DA affinity with decreased DA potency and Bmax and another that imparts increased DA affinity with a strikingly increased DA potency and Bmax. Overall, we show that a novel molecular interplay between EL3 and CT regulates multiple active conformations of D1-like receptors and may have potential implications for other G protein-coupled receptor classes.
Collapse
Affiliation(s)
- Katerina Tumova
- Ottawa Health Research Institute, Ottawa Hospital (Civic Campus), Ontario K1Y 4K9, Canada
| | | | | |
Collapse
|